Clinical Trial Update: A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State [Phase 4]

View source ↗

Summary

This report documents a completed Phase 4 pharmacokinetic (PK) study of natalizumab (Tysabri) at steady state in patients with multiple sclerosis. The study was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED